Expression of MUC5AC, an early marker of pancreatobiliary cancer, is regulated by DNA methylation in the distal promoter region in cancer cells

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 17, Issue 6, 2010, Pages 844-854

  Yamada, Norishige ^a,b   Nishida, Yukari ^a   Yokoyama, Seiya ^a   Tsutsumida, Hideaki ^a   Houjou, Izumi ^a   Kitamoto, Sho ^a   Goto, Masamichi ^a,c   Higashi, Michiyo ^a   Yonezawa, Suguru ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b RIKEN Center for Biosystems Dynamics Research   (Japan)

^c National Sanatorium Hoshizuka Keiaien   (Japan)

Author keywords

DNA methylation; Epigenetics; MassARRAY; MUC5AC; Mucin

Indexed keywords

DNA; HISTONE H3; LYSINE; MESSENGER RNA; MICRORNA; MUCIN 5AC; MUC5AC PROTEIN, HUMAN; RNA;

ARTICLE; BILE DUCT CANCER; BREAST CANCER; CANCER CELL CULTURE; CELL SPECIFICITY; CHROMATIN IMMUNOPRECIPITATION; COLON CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MAPPING; HISTONE MODIFICATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MICROARRAY ANALYSIS; NUCLEIC ACID ANALYSIS; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PANCREATOBILIARY CANCER; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN MICROARRAY; BILIARY TRACT TUMOR; BIOSYNTHESIS; COMPARATIVE STUDY; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PANCREAS TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; TUMOR CELL LINE;

BILIARY TRACT NEOPLASMS; CELL LINE, TUMOR; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MUCIN 5AC; PANCREATIC NEOPLASMS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TIME FACTORS;

EID: 79952198011     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1007/s00534-010-0278-0     Document Type: Article

References (39)

1. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2:897-909. (Pubitemid 37328891)
2. Isaji S, Kawarada Y, Uemoto S. Classification of pancreatic cancer: comparison of Japanese and UICC classifications. Pancreas. 2004;28:231-4. (Pubitemid 38437314)
3. Ishikawa O, Ohigashi H, Imaoka S, Nakaizumi A, Uehara H, Kitamura T, et al. Minute carcinoma of the pancreas measuring 1 cm or less in diameter-collective review of Japanese case reports. Hepatogastroenterology. 1999;46:8-15. (Pubitemid 29154713)
4. Egawa S, Takeda K, Fukuyama S, Motoi F, Sunamura M, Matsuno S. Clinicopathological aspects of small pancreatic cancer. Pancreas. 2004;28:235-40. (Pubitemid 38437315)
5. Inoue K, Makuuchi M, Takayama T, Torzilli G, Yamamoto J, Shimada K, et al. Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery. 2000;127:498-505. (Pubitemid 30257507)
6. Ohtsuka M, Ito H, Kimura F, Shimizu H, Togawa A, Yoshidome H, et al. Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg. 2002;89:1525-31. (Pubitemid 35404319)
7. Wade TP, Prasad CN, Virgo KS, Johnson FE. Experience with distal bile duct cancers in U.S. Veterans Affairs hospitals: 1987-1991. J Surg Oncol. 1997;64:242-5.
8. Fong Y, Blumgart LH, Lin E, Fortner JG, Brennan MF. Outcome of treatment for distal bile duct cancer. Br J Surg. 1996;83:1712-5. (Pubitemid 26421867)
9. Ouchi K, Matsuno S, Sato T. Long-term survival in carcinoma of the biliary tract. Analysis of prognostic factors in 146 resections. Arch Surg. 1989;124:248-52.
10. Yonezawa S, Sato E. Expression of mucin antigens in human cancers and its relationship with malignancy potential. Pathol Int. 1997;47:813-30. (Pubitemid 28087380)
11. Yonezawa S, Goto M, Yamada N, Higashi M, Nomoto M. Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior. Proteomics. 2008;8:3329-41.
12. Kim GE, Bae HI, Park HU, Kuan SF, Crawley SC, Ho JJ, et al. Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. Gastroenterology. 2002;123:1052-60.
13. Nagata K, Horinouchi M, Saitou M, Higashi M, Nomoto M, Goto M, et al. Mucin expression profile in pancreatic cancer and the precursor lesions. J Hepatobiliary Pancreat Surg. 2007;14:243-54. (Pubitemid 46863913)
14. Gratchev A, Siedow A, Bumke-Vogt C, Hummel M, Foss HD, Hanski ML, et al. Regulation of the intestinal mucin MUC2 gene expression in vivo: evidence for the role of promoter methylation. Cancer Lett. 2001;168:71-80. (Pubitemid 32463915)
15. Handra-Luca A, Lamas G, Bertrand JC, Fouret P. MUC1, MUC2, MUC4, and MUC5AC expression in salivary gland mucoepidermoid carcinoma: diagnostic and prognostic implications. Am J Surg Pathol. 2005;29:881-9. (Pubitemid 40885010)
16. Shibahara H, Tamada S, Goto M, Oda K, Nagino M, Nagasaka T, et al. Pathologic features of mucin-producing bile duct tumors: two histopathologic categories as counterparts of pancreatic intraductal papillary-mucinous neoplasms. Am J Surg Pathol. 2004;28:327-38. (Pubitemid 38269566)
17. Zen Y, Sasaki M, Fujii T, Chen TC, Chen MF, Yeh TS, et al. Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct-an immunohistochemical study of 110 cases of hepatolithiasis. J Hepatol. 2006;44:350-8. (Pubitemid 43069217)
18. Hamada T, Goto M, Tsutsumida H, Nomoto M, Higashi M, Sugai T, et al. Mapping of the methylation pattern of the MUC2 promoter in pancreatic cancer cell lines, using bisulfite genomic sequencing. Cancer Lett. 2005;227:175-84. (Pubitemid 41169931)
19. Yamada N, Hamada T, Goto M, Tsutsumida H, Higashi M, Nomoto M, et al. MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer. Int J Cancer. 2006;119:1850-7. (Pubitemid 44356842)
20. Yamada N, Nishida Y, Tsutsumida H, Hamada T, Goto M, Higashi M, et al. MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells. Cancer Res. 2008;68:2708-16. (Pubitemid 351556268)
21. Yamada N, Nishida Y, Tsutsumida H, Goto M, Higashi M, Nomoto M, et al. Promoter CpG methylation in cancer cells contributes to the regulation of MUC4. Br J Cancer. 2009;100:344-51.
22. Vincent A, Perrais M, Desseyn JL, Aubert JP, Pigny P, Van Seuningen I. Epigenetic regulation (DNA methylation, histone modifications) of the 11p15 mucin genes (MUC2, MUC5AC, MUC5B, MUC6) in epithelial cancer cells. Oncogene. 2007;26:6566-76. (Pubitemid 47530602)
23. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet. 2009;41:178-86.
24. Kondo Y, Shen L, Issa JP. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol. 2003;23:206-15. (Pubitemid 36008514)
25. Wolffe AP, Matzke MA. Epigenetics: regulation through repression. Science. 1999;286:481-6.
26. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5:522-31. (Pubitemid 38868508)
27. Nakahara K, Carthew RW. Expanding roles for miRNAs and siRNAs in cell regulation. Curr Opin Cell Biol. 2004;16:127-33. (Pubitemid 38757288)
28. Yonezawa S, Sueyoshi K, Nomoto M, Kitamura H, Nagata K, Arimura Y, et al. MUC2 gene expression is found in noninvasive tumors but not in invasive tumors of the pancreas and liver: its close relationship with prognosis of the patients. Hum Pathol. 1997;28:344-52. (Pubitemid 27106088)
29. Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos G, et al. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci USA. 2005;102:15785-90. (Pubitemid 41552820)
30. Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, Liang G, et al. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-20-deoxycytidine. Cancer Res. 2002;62:6456-61. (Pubitemid 35364106)
31. Mutskov V, Felsenfeld G. Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. EMBO J. 2004;23:138-49. (Pubitemid 38165754)
32. Shi H, Wei SH, Leu YW, Rahmatpanah F, Liu JC, Yan PS, et al. Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res. 2003;63:2164-71.
33. Ho JJ, Han SW, Pan PL, Deng G, Kuan SF, Kim YS. Methylation status of promoters and expression of MUC2 and MUC5AC mucins in pancreatic cancer cells. Int J Oncol. 2003;22:273-9.
34. Bird A. The essentials of DNA methylation. Cell. 1992;70:5-8.
35. Peters AH, O'Carroll D, Scherthan H, Mechtler K, Sauer S, Schofer C, et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell. 2001;107:323-37. (Pubitemid 33049976)
36. Lujambio A, Esteller M. CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle. 2007;6:1455-9.
37. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA. 2008;105:7004-9. (Pubitemid 351754520)
38. Saito Y, Jones PA. Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle. 2006;5:2220-2. (Pubitemid 44546557)
39. Medina PP, Slack FJ. microRNAs and cancer: an overview. Cell Cycle. 2008;7:2485-92.